^
    Back
    Association details:
    Biomarker:FGFR1 T141R
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:Alecensa (alectinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Natl Compr Canc Netw
    Title:

    Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma

    Excerpt:
    ...a 46-year-old man who presented with a locally advanced pancreatic head mass consistent with PDAC...FGFR1 missense mutation (c.422C>G, p.T141R)...The patient received external-beam RT to his thoracic spine and was started on alectinib. The duration of survival from diagnosis is 5 months at the time of writing.
    DOI:
    https://doi.org/10.6004/jnccn.2017.0058